Vol 22, No 2 (2020)

Guidelines
Hodgkin's lymphoma
Demina E.A., Tumyan G.S., Moiseeva T.N., Mikhailova N.B., Myakova N.V., Rumyantsev A.G., Maschan A.A., Kaplanov K.D., Shmakov R.G., Falaleeva N.A., Ptushkin V.V., Osmanov E.A., Poddubnaya I.V., Baikov V.V., Kovrigina A.M., Konovalov D.M., Trofimova O.P., Sotnikov V.M., Ilin N.V., Vinogradova Y.N., Nechesnyuk A.V., Parkhomenko R.A., Stefanov D.N., Nevolsky A.A., Ivanov S.A., Khaylova Z.V.
Abstract

Clinical recommendations.

Journal of Modern Oncology. 2020;22(2):6-33
views
Follicular lymphoma
Babicheva L.G., Tumyan G.S., Osmanov E.A., Falaleeva N.A., Kravchenko S.K., Stefanov D.N., Poddubnaya I.V., Myakova N.V., Rumyantsev A.G., Maschan A.A., Ptushkin V.V., Baikov V.V., Kovrigina A.M., Krivolapov I.A., Konovalov D.M., Nevolsky A.A., Ivanov S.A., Khaylova Z.V., Gevorkian T.G.
Abstract

Clinical recommendations.

Journal of Modern Oncology. 2020;22(2):34-51
views
Conference Proceedings
Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
Poddubnaya I.V., Baryakh E.A., Vorobyev V.I., Demina E.A., Zhukov N.V., Kaplanov K.D., Konstantinova T.S., Motorin D.V., Ptushkin V.V., Sarzhevsky V.O., Tumyan G.S.
Abstract

Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant pathology on the severity of infection show a significant increase in the risk of death from infection in male patients, aged >60 years, with the presence of ≥3 concomitant diseases, among which particularly negative role is played by diseases of the cardiovascular system, diabetes, oncology, chronic lung disease, immunodeficiency conditions. Particularly dangerous is the development of COVID-19 infection in an interval of less than 14 days from the course of antitumor therapy. At the same time, patients with Hodgkin lymphoma require immediate treatment, often associated with toxic, immunosuppressive therapy, frequent visits to the clinic, hospitalizations. International communities have not yet developed clear guidelines for the management of patients with Hodgkin’s lymphoma. Taking into account the understanding that the circulation of coronoviral infection will continue in the population, the Advisory board on the Problems of Hodgkin Lymphoma Therapy in the COVID-19 Pandemic is highly relevant.

Aim. To change and adapt current treatment approaches in the current epidemiological environment.

Results. The main directions of the impact of the COVID-19 pandemic on the treatment of patients with cancer pathology, including patients with classical Hodgkin lymphoma, were determined, key problems in the treatment of LC during the COVID-19 pandemic were identified, and measures aimed at reducing the risk for patients were developed. Existing approaches to first-line, relapse/refracturing cHL therapy, including salvage therapy, and auto/allo SCT during the COVID-19 pandemic, have been adapted.

Journal of Modern Oncology. 2020;22(2):52-55
views
New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas
Poddubnaya I.V., Ptushkin V.V., Belousova I.E., Gorenkova L.G., Kaplanov K.D., Karamova A.E., Kovrigina A.M., Kolomeitsev O.A., Konstantinova T.S., Kokhan M.M., Pospelova T.I.
Abstract

Relevance. Cutaneous T-cell lymphomas (CTCL) are not common diseases which are associated with a decrease in quality of life. Currently available systemic therapy rarely provides a stable and long-termed response. In Russia, current CTCL therapy is a big issue due to the limited access to modern targeted therapy, an absence of a National CTCL registry, and the difficulties in morphological diagnosis of these rare diseases. Since June 17, 2019, a new indication of brentuximab vedotin as a new treatment option for patients with CD30+ CTCL after at least one line of previous systemic therapy was registered. Brentuximab vedotin is a conjugate of a CD30 directed monoclonal antibody and an antitumor agent. Brentuximab vedotin is a CD30-directed monoclonal antibody conjugated to an antitumor agent.

Aim. To identify the unresolved issues of current clinical practice and to adapt available approaches to the treatment and diagnosis of CD30 + CTCL given new therapeutic opportunities.

Results. The available approaches to the systemic CTCL therapy in Russia routine clinical practice have been discussed, the unresolved issues of therapy and diagnosis have been identified, the routing of patients with CD30 + CTCL in Russia has been discussed, the importance of CD30 testing has been established, the profiles of patients with CTCL for treatment with brentuximab vedotin have been determined.

Journal of Modern Oncology. 2020;22(2):79-81
views
Новые возможности системной терапии CD30+ первичных кожных Т-клеточных лимфом. Резолюция
.
Abstract

Актуальность. Т-клеточные лимфомы кожи (ТКЛК) – это редкие, ассоциирующиеся со снижением качества жизни заболевания. Доступная на сегодняшний день системная терапия редко обеспечивает достижение стойкого и длительного ответа. В России в настоящий момент терапия ТКЛК представляет собой существенную проблему в связи с ограниченным доступом к современной таргетной терапии, отсутствием Национального регистра ТКЛК, сложностями морфологической диагностики данных редких заболеваний. С 17 июня 2019 г. зарегистрировано новое показание брентуксимаба ведотина – в качестве новой опции лечения пациентов с CD30+ ТКЛК после минимум одной линии предшествующей системной терапии. Брентуксимаб ведотин представляет собой конъюгат CD30-направленного моноклонального антитела и противоопухолевого агента.

Цель. Выявить нерешенные проблемы текущей клинической практики и адаптировать существующие подходы к лечению и диагностике CD30+ ТКЛК с учетом новых терапевтических возможностей.

Результаты. Обсуждены существующие подходы к системной терапии ТКЛК в рутинной клинической практике России, определены нерешенные проблемы терапии и диагностики, обсуждена маршрутизация пациентов с CD30+ ТКЛК в России, определена важность CD30-тестирования, определены профили пациентов с ТКЛК на терапию брентуксимабом ведотином.

Journal of Modern Oncology. 2020;22(2):79-81
views
Lecture
Особенности ведения онкологических пациентов во время пандемии коронавирусной инфекции COVID-19
., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., .
Abstract

Учебный модуль разработан коллективом кафедры под руководством зав. кафедрой академика РАН, профессора И.В. Поддубной и ректора ФГБОУ ДПО РМАНПО Минздрава России, чл.-кор. РАН, профессора Д.А. Сычева.

Journal of Modern Oncology. 2020;22(2):56-73
views
Original Article
Maintenance oncohematological patients and new coronavirus infection: experience of the City Clinical Hospital №52
Baryakh E.A., Kochneva O.L., Misyurina E.N., Zhelnova E.I., Yatskov K.V., Zagrebneva A.I., Zyangirov R.R., Samsonova I.V., Poteshkina N.G., Lysenko M.A., Poddubnaya I.V.
Abstract

Justification. Oncological diseases, along with diabetes, hypertension, cardiovascular and chronic obstructive pulmonary diseases, are associated with severe course and worst prognosis of the new coronavirus infection – COVID-19. Due to the limited number of the international studies and the lack of the domestic publications on the analysis of the course of COVID-19 in patients with oncohematological pathology and the patient management tactics, this work seems extremely topical.

Materials and methods. 24.04.2020–31.05.2020, 110 patients with oncohematological pathology associated with new coronavirus infection were observed on the basis of the hematology service of City Clinical Hospital №52: 59 women and 51 men, mean age 58 (18–90) years.

Results. Currently, 24 (22%) patients among 110 are continuing treatment. The outcome of the disease is observed in 86 (78%) patients: 50 (58%) patients were discharged from hospital with complete or partial resolution of pneumonia, 36 (42%) of the 86 patients died. The groups did not differ in gender. The median age was higher in the group of deceased patients (66 vs. 54 years in patients who had a favorable outcome after COVID-19). The somatic status ECOG 3–4 was an independent predictive factor determining the adverse outcome of the disease. The third part of the patients from the group with a fatal cases due to a severe condition in the debut of the disease immediately were hospitalized in the intensive care unit (ICU), 2 (6%) of them had died within the first day. Disposition, according to the nosology showed a significant predominance among patients with an adverse outcome associated with acute leukemia (18% vs 39%). Patients with resistant course of hemoblastosis accounted for 50% of deceased patients. Severe form of the course of COVID-19 infection was twice as frequently (46% vs 84%) among patients with an adverse outcome of the disease, that was associated with both the initial more severe group of patients (33% were hospitalized in the ICU), and less curability of pneumonia against the background of the adverse prognostic factors: the older age group, the predominance of patients with acute leukemia and resistant course of oncohematological diseases. Specific anticancer therapy and COVID-19 therapy were comparable in both groups.

Conclusions. Identification of new coronavirus infection against a backdrop of oncohematological disease is associated with a severe course of COVID-19 and high death rate – 42%. According to the preliminary obtained results, the adverse prognostic factors of COVID-19 in patients with oncohematological diseases include: elderly age, the poor somatic status (ECOG 3–4), relapse or progression of hemoblastosis and nosological affiliation to acute leukemia.

Journal of Modern Oncology. 2020;22(2):74-78
views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies